COCO SILVIA

Meanti, R., Bresciani, E., Rizzi, L., Molteni, L., Coco, S., Omeljaniuk, R., et al. (2025). Cannabinoid Receptor 2 (CB2R) as potential target for the pharmacological treatment of neurodegenerative diseases. BIOMÉDECINE & PHARMACOTHÉRAPIE, 186 [10.1016/j.biopha.2025.118044]. Dettaglio

Meanti, R., Bresciani, E., Rizzi, L., Coco, S., Zambelli, V., Dimitroulas, A., et al. (2023). Potential Applications for Growth Hormone Secretagogues Treatment of Amyotrophic Lateral Sclerosis. CURRENT NEUROPHARMACOLOGY, 21(12), 2376-2394 [10.2174/1570159X20666220915103613]. Dettaglio

Meanti, R., Licata, M., Rizzi, L., Bresciani, E., Molteni, L., Coco, S., et al. (2023). Protective Effects of Hexarelin and JMV2894 in a Human Neuroblastoma Cell Line Expressing the SOD1-G93A Mutated Protein. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(2) [10.3390/ijms24020993]. Dettaglio

Rizzi, L., Turati, M., Bresciani, E., Anghilieri, F., Meanti, R., Molteni, L., et al. (2022). Characterization of microRNA Levels in Synovial Fluid from Knee Osteoarthritis and Anterior Cruciate Ligament Tears. BIOMEDICINES, 10(11) [10.3390/biomedicines10112909]. Dettaglio

Meanti, R., Rizzi, L., Bresciani, E., Molteni, L., Locatelli, V., Coco, S., et al. (2021). Hexarelin modulation of mapk and pi3k/akt pathways in neuro-2a cells inhibits hydrogen peroxide-induced apoptotic toxicity. PHARMACEUTICALS, 14(5) [10.3390/ph14050444]. Dettaglio